Core Insights - The topic of "Northwest University Vice President Fan Daidi becomes the richest person in Shaanxi" has gained significant attention on social media, highlighting the wealth of Fan Daidi and her husband Yan Jianya, who own two listed companies: Juzhi Biotechnology and Triangle Defense [2] - According to the 2025 Hurun Global Rich List, Fan Daidi and her husband have a combined net worth of 31.5 billion yuan, surpassing other notable figures in the region [2] Company Overview - Juzhi Biotechnology, founded in 2000, specializes in the research, production, and sales of recombinant collagen and other bioactive components, and was listed on the Hong Kong Stock Exchange in November 2022 [3][4] - Fan Daidi, a co-founder of Juzhi Biotechnology, served as the executive director until July 2023 and has a long-standing affiliation with Northwest University, where she has held various academic positions [3][4] Market Dynamics - The recombinant collagen market is experiencing rapid growth, with a projected market size increase from 18.5 billion yuan in 2022 to 108.3 billion yuan by 2027, reflecting a compound annual growth rate (CAGR) of 42.4% [4] - Both Juzhi Biotechnology and Jinbo Biotechnology are showing high growth rates, with Juzhi's revenue reaching 5.539 billion yuan in 2024, a year-on-year increase of 57.2%, while Jinbo's revenue grew by 84.92% to 1.443 billion yuan [5] Financial Performance - Juzhi Biotechnology reported an adjusted net profit of 2.152 billion yuan in 2024, up 46.5% year-on-year, while Jinbo's net profit surged by 144.27% to 732 million yuan [5] - Both companies maintain high gross margins, with Juzhi's gross margin at 82.09% and Jinbo's at 92.02% in 2024 [6] Competitive Landscape - The competition in the recombinant collagen sector is intensifying, with established players like Huaxi Biotechnology and Aimeike entering the market, alongside new entrants like Hangzhou Meiliu Biotechnology, which has significantly reduced production costs [6][9] - Juzhi Biotechnology's revenue heavily relies on its core brand, Kefu Mei, which accounts for over 80% of its revenue, and the company is increasingly dependent on online sales channels, which constituted 71.6% of total revenue in 2024 [6][7] Product Development Challenges - Juzhi Biotechnology has plans to enter the recombinant collagen injection market, with two products expected to be approved in 2024, but currently, its registration is limited to dressing products [7][8] - Jinbo Biotechnology has achieved breakthroughs in the third-class medical device sector, holding all three existing registrations for recombinant collagen medical devices in China, but also faces challenges with revenue concentration [8][9]